Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.

ClinicalTrials.gov ID: NCT00348894

Public ClinicalTrials.gov record NCT00348894. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b Long-Term, Randomized, Open-Label, Safety And Tolerability Trial Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care In Patients With Chronic Painful Diabetic Peripheral Neuropathy (DPN).

Study identification

NCT ID
NCT00348894
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
136 participants

Conditions and interventions

Conditions

Interventions

  • [S,S]-Reboxetine Drug
  • Any Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2006
Primary completion
Sep 30, 2007
Completion
Sep 30, 2007
Last update posted
May 31, 2011

2006 – 2007

United States locations

U.S. sites
24
U.S. states
16
U.S. cities
23
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35233
Pfizer Investigational Site Birmingham Alabama 35294
Pfizer Investigational Site Phoenix Arizona 85050
Pfizer Investigational Site Scottsdale Arizona 85254
Pfizer Investigational Site Jonesboro Arkansas 72401
Pfizer Investigational Site Auburn California 95602
Pfizer Investigational Site Huntington Beach California 92648
Pfizer Investigational Site Orangevale California 95662
Pfizer Investigational Site Naples Florida 34102
Pfizer Investigational Site Winter Park Florida 32789
Pfizer Investigational Site Honululu Hawaii 96814
Pfizer Investigational Site Chicago Illinois 60610
Pfizer Investigational Site Columbia Missouri 65212
Pfizer Investigational Site Jefferson City Missouri 65109
Pfizer Investigational Site St Louis Missouri 63141
Pfizer Investigational Site Omaha Nebraska 68105
Pfizer Investigational Site Las Vegas Nevada 89148
Pfizer Investigational Site Reno Nevada 89509
Pfizer Investigational Site Nashua New Hampshire 03063
Pfizer Investigational Site Syracuse New York 13210
Pfizer Investigational Site Greensboro North Carolina 27408
Pfizer Investigational Site Dallas Texas 75246
Pfizer Investigational Site Richmond Virginia 23225
Pfizer Investigational Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00348894, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 31, 2011 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00348894 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →